all report title image
  • Published On : May 2022
  • Code : CMI5019
  • Industry : Pharmaceutical
  • Pages : 175
  • Formats :

Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. Inhibitors of the mammalian target of rapamycin are a new class of immunosuppressants. There are three commercially available mammalian (mechanistic) target of rapamycin (mTOR) inhibitors approved by the U.S. Food and Drug Administration (FDA) approved: sirolimus, everolimus, and temsirolimus. Mammalian target of rapamycin (mTOR) inhibitors are used in the treatment of renal cancer and is being studied for use in other types of cancers. Mechanistic target of rapamycin (mTOR) inhibitors provides more benefits when used with chemotherapy agents to treat cancers.

Global mTOR Inhibitors Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic has negatively impacted the growth of global mTOR inhibitors market. The COVID-19 pandemic affected the health care systems globally and resulted in the interruption of usual care in many health care facilities, exposing vulnerable patients with cancer to significant risks. Our study aimed to evaluate the impact of this pandemic on cancer care worldwide. According to an article published by American Society of Clinical Oncology, in September 2020, a survey was conducted by An American Society of Clinical Oncology Journal, total of 356 centers from 54 countries across six continents participated between April 21 and May 8, 2020. These centers serve 716,979 new patients with cancer a year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% reduced services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), staff shortage (17.98%), and restricted access to medications (9.83%).  Participants reported patient exposure to harm from interruption of cancer-specific care (36.52%) and non-cancer-related care (39.04%), with some centers estimating that up to 80% of their patients were exposed to harm. Thus, the COVID-19 has negatively impacted the global mTOR inhibitors market.

Global mTOR inhibitors market is estimated to be valued at US$ 6,704.5 thousand in 2022 and expected to exhibit a CAGR of 4.5% over the forecast period (2022-2030).

Figure 1: Global mTOR Inhibitors Market Share (%) Analysis, By Drug Type, 2022

 mTOR Inhibitors  | Coherent Market Insights

The increasing number of generic drug launches by the market players is expected to drive the growth of global mTOR inhibitors market over the forecast period.

Market players are focused on organic growth strategies such as drug launches, which is expected to drive the market growth over the forecast period. For instance, in February 2018, Biocon Ltd., a biopharmaceutical company announced the launch of Everolimus tablets, a generic version of Afinitor, in the U.S. Everolimus tablets will be introduced in 2.5mg, 5mg, 7.5mg and 10mg strengths.

CMI table icon

mTOR Inhibitors Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2022: US$ 6,704.5 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2022 to 2030
Forecast Period 2020 to 2027 CAGR: 4.5% 2030 Value Projection: US$ 9,534.5 Mn
Geographies covered:
  • Region: North America, Latin America, Europe, Asia Pacific, Middle East, Africa
Segments covered:
  • By Drug Type: Everolimus, Temsirolimus, Sirolimus
  • By Indication: Oncology, Immunosuppressant, Organ Transplantation, Others
  • By Route of Administration: Oral, Intravenous
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Novartis AG, Hikma Pharmaceuticals PLC., Par Pharmaceutical, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Cadilla, Pfizer, Inc., Biocon, Alkem Laboratories Ltd., Accord Healthcare Inc., Gland Pharma Ltd., Apotex Inc., and Glenmark Pharmaceuticals Ltd.

Growth Drivers:
  • The increasing number of generic drug launches
  • Increasing number of product approvals from regulatory bodies.
Restraints & Challenges:
  • High price of drugs

The increasing number of product approvals from regulatory bodies is expected to drive the growth of global mTOR inhibitors market over the forecast period.

Market players are focused on gaining product approvals from regulatory bodies, which is expected to drive the growth of global mTOR inhibitors market over the forecast period. For instance, in October 2020, Glenmark Pharmaceuticals, a pharmaceutical company, announced that the U.S. Food and Drug Administration has approved generic version of Rapamune tablets, 0.5mg, 1mg and 2mg. The drug is the generic version of Pfizer, Inc. and Wyeth Pharmaceuticals, a pharmaceutical company’s Rapamune tablets.   

Global mTOR Inhibitors Market – Restraints

The high price of drugs (including branded and generic) is a major hurdle for the market growth. For instance, according to Drugs. Com., the price of Temsirolimus intravenous solution (25mg/mL), indicated for the treatment of advanced renal cell carcinoma is around US$ 1,213.

Global mTOR Inhibitors Market – Region Analysis

On the basis of region, global mTOR inhibitors market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa.

North America is expected to hold a dominant position in the market during the forecast period, owing to increasing number of product approvals from regulatory bodies in the region. For instance, in February 2016, Novartis AG, a pharmaceutical company, announced that the U.S.Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.

Figure 2: Global mTOR Inhibitors Market (US$ Mn), by Country, 2022

mTOR Inhibitors  | Coherent Market Insights

Global mTOR Inhibitors Market – Competitive Landscape

Major players operating in global mTOR inhibitors market include Novartis AG, Hikma Pharmaceuticals PLC., Par Pharmaceutical, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Cadilla, Pfizer, Inc., Biocon, Alkem Laboratories Ltd., Accord Healthcare Inc., Gland Pharma Ltd., Apotex Inc., and Glenmark Pharmaceuticals Ltd. 

Mammalian target of rapamycin (mTOR) is a protein kinase, which regulates growth factors that stimulate cell growth and angiogenesis. Mammalian target of rapamycin (mTOR) inibitors controls the cell division, and controls the growth of cancer cells from growing and prevent the growth of new blood vessels that tumors need to grow. Mammalian target of rapamycin (mTOR) inhibitors are used in the treatment of renal cancer and it is being studied for use in other types of cancers. mTOR are indicated for the treatment of breast cancer, lymphangioleiomyomatosis, neuroendocrine carcinoma, organ transplant, pancreatic cancer, renal cell carcinoma, tuberous sclerosis complex and others. Mammalian target of rapamycin (mTOR), drugs are- Everolimus, Temsirolimus, and Sirolimus. Mammalian target of rapamycin (mTOR) has common and serious class side effects of mTOR inhibitors include non-infectious pneumonitis, metabolic disorders and mucosal toxicity.

Market Dynamics

Increasing product approvals from regulatory bodies is expected to drive the growth of global mTOR Inhibitors market during the forecast period. For instance, in June 2021, Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical announced that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Everolimus Tablets (generic for Zortress). Everolimus tablets will be in strength of 0.25mg, 0.5mg, and 0.75mg.

Increasing number of prevalence of renal cell carcinoma is expected to drive the growth of global mTOR inhibitors market. For instance, according to an article published by the U.S. Department of Health and Human Services, published in 2018, there were an estimated 582,727 people living with kidney and renal pelvis cancer in the U.S.

Key features of the study:

  • This report provides an in-depth analysis of global mTOR inhibitors market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global mTOR inhibitors market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
  • Key companies covered as a part of this study include Novartis AG, Hikma Pharmaceuticals PLC., Par Pharmaceutical, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Cadilla, Pfizer, Inc., Biocon, Alkem Laboratories Ltd., Accord Healthcare Inc., Gland Pharma Ltd., Apotex Inc., and Glenmark Pharmaceuticals Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global mTOR inhibitors market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global mTOR inhibitors

Detailed Segmentation:

  • Global mTOR Inhibitors Market, By Drug Type:
    • Everolimus
    • Temsirolimus
    • Sirolimus
  • Global mTOR Inhibitors Market, By Indication:
    • Oncology
    • Immunosuppressant
    • Organ Transplantation
    • Others
  • Global mTOR Inhibitors Market, By Route of Administration:
    • Oral
    • Intravenous
  • Global mTOR Inhibitors Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global mTOR Inhibitors Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Novartis AG*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Hikma Pharmaceuticals PLC.
    • Par Pharmaceutical
    • Teva Pharmaceutical Industries Ltd.
    • Reddy’s Laboratories Ltd.
    • Zydus Cadilla
    • Pfizer, Inc.
    • Biocon
    • Alkem Laboratories Ltd.
    • Accord Healthcare Inc.
    • Gland Pharma Ltd.
    • Apotex Inc.
    • Glenmark Pharmaceuticals Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global mTOR inhibitors market is expected to exhibit a CAGR of 4.5% during the forecast period (2022-2030).
The market is estimated to be valued at US$ 6,704.5 Mn in 2022.
Novartis AG, Hikma Pharmaceuticals PLC., Par Pharmaceutical, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Cadilla, Pfizer, Inc., Biocon, Alkem Laboratories Ltd., Accord Healthcare Inc., Gland Pharma Ltd., Apotex Inc., and Glenmark Pharmaceuticals Ltd. are some of the prominent players operating in the market.
The market is expected to be valued at US$ 9,534.5 Mn in 2030.
North America is the prominent region in the market
Everolimus, which belongs to the drug type segment, is the prominent segment in the market

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo